Management of persistent vaginitis

Obstetrics and Gynecology

Volumn 124, Issue 6, 2014, Pages 1135-1146

  Nyirjesy, Paul ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; ESTROGEN; FLUCONAZOLE; HYALURONIC ACID; HYDROCORTISONE; KETOCONAZOLE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OSPEMIFENE; PAROMOMYCIN; PRASTERONE; TINIDAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; CANDIDIASIS; DESQUAMATIVE INFLAMMATORY VAGINITIS; EVALUATION STUDY; FEMALE; HUMAN; TRICHOMONIASIS; UNITED STATES; VAGINA ATROPHY; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINITIS; CHRONIC DISEASE; SECRETION (PROCESS); VAGINA;

CHRONIC DISEASE; FEMALE; HUMANS; VAGINA; VAGINITIS;

EID: 84916911991     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000551     Document Type: Article

References (58)

1. Lipsky MS, Waters T, Sharp LK. Impact of vaginal antifungal products on utilization of health care services: evidence from physician visits. J Am Board Fam Pract 2000;13:178-82.
2. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA 2004;291:1368-79.
3. Nyirjesy P, Robinson J, Mathew L, Lev-Sagie A, Reyes I, Culhane JF. Alternative therapies in women with chronic vaginitis. Obstet Gynecol 2011;117:856-61.
4. Nyirjesy P, Peyton C, Weitz MV, Mathew L, Culhane JF. Causes of chronic vaginitis: analysis of a prospective database of affected women. Obstet Gynecol 2006;108:1185-91.
5. Diagnosis and management of vulvar skin disorders. ACOG Practice Bulletin No. 93. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008;111:1243-53.
6. Vaginitis. ACOG Practice Bulletin No. 72. American College of Obstetricians and Gynecologists. Obstet Gynecol 2006;107: 1195-206.
7. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted disease treatment guidelines, 2010. MMWR Recomm Rep 2010;59:1-110.
8. Nyirjesy P, Sobel JD. Advances in diagnosing vaginitis: development of a new algorithm. Cur Infect Dis Rep 2005; 7:458-62.
9. Hillier SL. Normal genital flora. In: Holmes KK, Sparling PF, Mårdh P-A, Lemon SM, Stamm WE, Piot P, et al, editors. Sexually transmitted diseases. 3rd ed. New York (NY): McGraw-Hill; 1999. p. 191-203.
10. Marrazzo JM. Vulvovaginal candidiasis. BMJ 2003;326:993-4.
11. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Candida vaginitis: self- reported incidence and associated costs. Sex Transm Dis 2000;27:230-5.
12. Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 1998;92:757-65.
13. Bergman JJ, Berg AO, Schneeweis R, Heidrich FE. Clinical comparison of microscopic and culture techniques in the diagnosis of Candida vaginitis. J Fam Pract 1984;18:549-52.
14. Ledger WJ, Polaneczky MM, Yih MC, Jeremias J, Tolbert V, Witkin SS. Difficulties in the diagnosis of Candida vaginitis. Infect Dis Clin Pract 2000;9:66-9.
15. Vergers-Spooren H, van der Meijden WI, Luijendijk A, Donders G. Self-sampling in the diagnosis of recurrent vulvovaginal candidosis. J Low Genit Tract Dis 2013;17:187-92.
16. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 2004;104:926-30.
17. Hong E, Dixit S, Fidel PL, Bradford J, Fischer G. Vulvovaginal candidiasis as a chronic disease: diagnostic criteria and definition. J Low Genit Tract Dis 2014;18:31-8.
18. de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type I and type II diabetes. BMC Infect Dis 2002;2:1. [Epub 2002 Jan 30].
19. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28:1173-8.
20. Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Microbiol 2006;44:3213-7.
21. Fischer G, Bradford J. Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. J Low Genit Tract Dis 2011;15:263-7.
22. Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996;7:182-7.
23. Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am 2008;22:637-52, vi.
24. Giraldo P, von Nowaskonski A, Gomes FA, Linhares I, Neves NA, Witkin SS. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet Gynecol 2000;95:413-6.
25. Fidel PL Jr, Barousse M, Espinosa T, et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004;72:2939-46.
26. Sobel JD. Vulvovaginal candidosis. Lancet 2007;369:1961-71.
27. Nyirjesy P, Seeney SM, Grody MHT, Jordan CA, Buckley HR. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995;173:820-3.
28. Kennedy MA, Sobel JD. Vulvovaginal candidiasis caused by Non-albicans Candida Species: New Insights. Curr Infect Dis Rep 2010;12:465-70.
29. Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001;185:363-9.
30. Sobel JD, Weisenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004;351:876-83.
31. Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012;120:1407-14.
32. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003;189:1297-300.
33. Phillips AJ. Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol 2005;192:2009-12.
34. Nyirjesy P, Alexander AB, Weitz MV. Vaginal Candida parapsilosis: pathogen or bystander? Infect Dis Obstet Gynecol 2005;13:37-41.
35. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 2007;109:114-20.
36. Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 2007;45:3270-6.
37. Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol 2004; 190:1004-10.
38. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006;193:1478-86.
39. Bradshaw CS, Tabrizi SN, Fairley CK, Morton AN, Rudland E, Garland SM. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis 2006;194:828-36.
40. Gardner HL, Dukes CD. Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis. Am J Obstet Gynecol 1955;69: 962-76.
41. Verstraelen H, Swidsinski A. The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment. Curr Opin Infect Dis 2013;26:86-9.
42. Muzny CA, Schwebke JR. Gardnerella vaginalis: Still a Prime Suspect in the Pathogenesis of Bacterial Vaginosis. Curr Infect Dis Rep 2013;15:130-5.
43. Sobel JD, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld HC, Peipert J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006;194:1283-9.
44. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009;36:732-4.
45. Helms DJ, Mosure DJ, Metcalf CA, Douglas JM, Malotte K, Paul SM, et al. Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics. Sex Transm Dis 2008;35:484-8.
46. Dan M, Sobel JD. Trichomoniasis as seen in a chronic vaginitis clinic. Infect Dis Obstet Gynecol 1996;4:77-84.
47. Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008;198:370.e1-7.
48. Krashin JW, Koumans EH, Bradshaw-Sydnor AC, Braxton JR, Secor WE, Sawyer MK, et al. Trichomonas vaginalis prevalence, incidence, risk factors and antibioticresistance in an adolescent population. Sex Transm Dis 2009;37:440-4.
49. Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001;33:1341-6.
50. Nyirjesy P, Gilbert J, Mulcahy LJ. Resistant trichomoniasis: successful treatment with combination therapy. Sex Transm Dis 2011;38:962-3.
51. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902.
52. Nyirjesy P, Leigh RD, Mathew L, Lev-Sagie A, Culhane JF. Chronic vulvovaginitis in women older than 50 years: analysis of a prospective database. J Low Genit Tract Dis 2012; 16:24-9.
53. Ekin M, Yaşar L, Savan K, Temur M, Uhri M, Gencer I, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet 2011;283:539-43.
54. Gray LA, Barnes ML. Vaginitis in women, diagnosis and treatment. Am J Obstet Gynecol 1965;92:125-36.
55. Sobel JD. Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol 1994;171: 1215-20.
56. Edwards L, Friedrich EG Jr. Desquamative vaginitis: lichen planus in disguise. Obstet Gynecol 1988;71:832-6.
57. Pereira N, Edlind TD, Schlievert PM, Nyirjesy P. Vaginal toxic shock reaction triggering desquamative inflammatory vaginitis. J Low Genit Tract Dis 2013;17:88-91.
58. Sobel JD, Reichman O, Misra D, Yoo W. Prognosis and treatment of desquamative inflammatory vaginitis. Obstet Gynecol 2011;117:850-5.